Plant Name: Croton nitens
Collective Molecular Activities at 10μM Activity Cutoff
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| NPSR1; | |
| CTDSP1; TDP1; HSD17B1; AKR1B1; HSD17B2; ALOX15; NOX4; | |
| DAPK1; FLT3; | |
| CA2; CA12; CA7; | |
| AR; NR3C1; | |
| NR0B1; | |
| ESRRA; | |
| ALOX5; TYR; XDH; | |
| AHR; HIF1A; TP53; | |
| ABCG2; ABCC1; | |
| HTT; NPC1; LMNA; PAX8; RAB9A; | |
| SMN1;SMN2; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
Detailed Information of Human Protein Targets
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| ATP-binding cassette | ABCG2 | ATP-binding cassette sub-family G member 2 | Q9UNQ0 | CHEMBL5393 |
| ATP-binding cassette | ABCC1 | Multidrug resistance-associated protein 1 | P33527 | CHEMBL3004 |
| Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
| Cytochrome P450 family 1 | CYP1B1 | Cytochrome P450 1B1 | Q16678 | CHEMBL4878 |
| Cytochrome P450 family 1 | CYP1A1 | Cytochrome P450 1A1 | P04798 | CHEMBL2231 |
| Cytochrome P450 family 2 | CYP2C19 | Cytochrome P450 2C19 | P33261 | CHEMBL3622 |
| Cytochrome P450 family 2 | CYP2C9 | Cytochrome P450 2C9 | P11712 | CHEMBL3397 |
| Cytochrome P450 family 3 | CYP3A4 | Cytochrome P450 3A4 | P08684 | CHEMBL340 |
| Enzyme_unclassified | CTDSP1 | Carboxy-terminal domain RNA polymerase II polypeptide A small phosphatase 1 | Q9GZU7 | CHEMBL1795098 |
| Enzyme_unclassified | TDP1 | Tyrosyl-DNA phosphodiesterase 1 | Q9NUW8 | CHEMBL1075138 |
| Enzyme_unclassified | HSD17B1 | Estradiol 17-beta-dehydrogenase 1 | P14061 | CHEMBL3181 |
| Enzyme_unclassified | AKR1B1 | Aldose reductase | P15121 | CHEMBL1900 |
| Enzyme_unclassified | HSD17B2 | Estradiol 17-beta-dehydrogenase 2 | P37059 | CHEMBL2789 |
| Enzyme_unclassified | ALOX15 | Arachidonate 15-lipoxygenase | P16050 | CHEMBL2903 |
| Enzyme_unclassified | NOX4 | NADPH oxidase 4 | Q9NPH5 | CHEMBL1250375 |
| Lyase | CA2 | Carbonic anhydrase II | P00918 | CHEMBL205 |
| Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
| Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
| Methyl-lysine/arginine binding protein | SMN1;SMN2 | Survival motor neuron protein | Q16637 | CHEMBL1293232 |
| Nuclear hormone receptor subfamily 0 group B | NR0B1 | Nuclear receptor subfamily 0 group B member 1 | P51843 | CHEMBL1795094 |
| Nuclear hormone receptor subfamily 3 group B | ESRRA | Estrogen-related receptor alpha | P11474 | CHEMBL3429 |
| Nuclear hormone receptor subfamily 3 group C | AR | Androgen Receptor | P10275 | CHEMBL1871 |
| Nuclear hormone receptor subfamily 3 group C | NR3C1 | Glucocorticoid receptor | P04150 | CHEMBL2034 |
| Oxidoreductase | XDH | Xanthine dehydrogenase | P47989 | CHEMBL1929 |
| Oxidoreductase | ALOX5 | Arachidonate 5-lipoxygenase | P09917 | CHEMBL215 |
| Oxidoreductase | TYR | Tyrosinase | P14679 | CHEMBL1973 |
| Peptide receptor (family A GPCR) | NPSR1 | Neuropeptide S receptor | Q6W5P4 | CHEMBL5162 |
| Protein Kinase | DAPK1 | Death-associated protein kinase 1 | P53355 | CHEMBL2558 |
| Protein Kinase | FLT3 | Tyrosine-protein kinase receptor FLT3 | P36888 | CHEMBL1974 |
| Transcription Factor | AHR | Aryl hydrocarbon receptor | P35869 | CHEMBL3201 |
| Transcription Factor | HIF1A | Hypoxia-inducible factor 1 alpha | Q16665 | CHEMBL4261 |
| Transcription Factor | TP53 | Cellular tumor antigen p53 | P04637 | CHEMBL4096 |
| Unclassified | HTT | Huntingtin | P42858 | CHEMBL5514 |
| Unclassified | NPC1 | Niemann-Pick C1 protein | O15118 | CHEMBL1293277 |
| Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
| Unclassified | PAX8 | Paired box protein Pax-8 | Q06710 | CHEMBL2362980 |
| Unclassified | RAB9A | Ras-related protein Rab-9A | P51151 | CHEMBL1293294 |
Enrichment of Gene Ontology of Target Proteins (Activity≤10μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| MF | GO:0005488; binding | GO:0019825; oxygen binding | 2.730E-12 | 2.698E-08 | CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9, CYP3A4, NOX4 |
| BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 5.608E-12 | 3.053E-08 | CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9 |
| MF | GO:0005488; binding | GO:0005506; iron ion binding | 1.943E-11 | 8.340E-08 | ALOX15, ALOX5, CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9, CYP3A4, XDH |
| BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 1.904E-10 | 4.146E-07 | CYP1A2, CYP2C19, CYP2C9, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 4.458E-10 | 8.824E-07 | CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9 |
| MF | GO:0005488; binding | GO:0020037; heme binding | 5.060E-09 | 5.799E-06 | CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9, CYP3A4, NOX4 |
| BP | GO:0050896; response to stimulus | GO:0042738; exogenous drug catabolic process | 6.231E-09 | 6.784E-06 | CYP1A2, CYP2C19, CYP2C9, CYP3A4 |
| MF | GO:0005488; binding | GO:0005496; steroid binding | 1.607E-08 | 1.458E-05 | AR, CYP3A4, ESRRA, HSD17B1, NPC1, NR3C1 |
| MF | GO:0003824; catalytic activity | GO:0034875; caffeine oxidase activity | 2.806E-08 | 2.037E-05 | CYP1A2, CYP2C9, CYP3A4 |
| MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 1.097E-07 | 6.289E-05 | CYP1A1, CYP1A2, CYP1B1, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0070989; oxidative demethylation | 1.527E-06 | 6.147E-04 | CYP1A2, CYP2C9, CYP3A4 |
| BP | GO:0032502; developmental process | GO:0048513; animal organ development | 1.712E-06 | 6.658E-04 | AR, CA2, CYP1A1, CYP1A2, ESRRA, FLT3, HIF1A, HSD17B2, HTT, NR0B1, PAX8, TYR |
| BP | GO:0050896; response to stimulus | GO:0010038; response to metal ion | 2.551E-06 | 9.258E-04 | ALOX15, CA2, CYP1A1, CYP1A2, HIF1A, NPC1, TP53 |
| MF | GO:0140110; transcription regulator activity | GO:0004879; nuclear receptor activity | 2.531E-06 | 9.258E-04 | AHR, AR, ESRRA, NR0B1 |
| MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 3.144E-06 | 1.104E-03 | CA12, CA2, CA7 |
| BP | GO:0050896; response to stimulus | GO:1901700; response to oxygen-containing compound | 3.786E-06 | 1.309E-03 | AKR1B1, AR, CYP1A1, CYP1A2, CYP1B1, DAPK1, ESRRA, HSD17B2, NOX4, NR3C1, TP53, TYR |
| BP | Unclassified; | GO:0032846; positive regulation of homeostatic process | 4.846E-06 | 1.552E-03 | CA2, CA7, HIF1A, HTT, NPC1, NPSR1 |
| MF | GO:0060089; molecular transducer activity | GO:0003707; steroid hormone receptor activity | 5.362E-06 | 1.622E-03 | AR, ESRRA, NR0B1, NR3C1 |
| BP | GO:0009987; cellular process | GO:0032849; positive regulation of cellular pH reduction | 1.129E-05 | 3.152E-03 | CA2, CA7 |
| MF | GO:0003824; catalytic activity | GO:0070576; vitamin D 24-hydroxylase activity | 1.129E-05 | 3.152E-03 | CYP1A1, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0009404; toxin metabolic process | 1.211E-05 | 3.337E-03 | CYP1A1, CYP1A2, CYP1B1 |
| BP | GO:0050896; response to stimulus | GO:0035902; response to immobilization stress | 1.382E-05 | 3.582E-03 | CYP1A1, CYP1A2, NR0B1 |
| BP | GO:0008152; metabolic process | GO:2000377; regulation of reactive oxygen species metabolic process | 1.920E-05 | 4.918E-03 | CYP1B1, HIF1A, NOX4, TP53, XDH |
| BP | GO:0008152; metabolic process | GO:0018894; dibenzo-p-dioxin metabolic process | 2.256E-05 | 5.495E-03 | CYP1A1, CYP1A2 |
| BP | GO:0009987; cellular process | GO:0030522; intracellular receptor signaling pathway | 2.271E-05 | 5.495E-03 | AHR, AR, ESRRA, NR0B1, NR3C1 |
| MF | GO:0005488; binding | GO:0043167; ion binding | 2.607E-05 | 6.237E-03 | ABCC1, ABCG2, ALOX15, ALOX5, AR, CA12, CA2, CA7, CTDSP1, CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9, CYP3A4, DAPK1, ESRRA, FLT3, HSD17B1, NOX4, NR3C1, RAB9A, TP53, TYR, XDH |
| BP | GO:0065007; biological regulation | GO:0098771; inorganic ion homeostasis | 2.916E-05 | 6.754E-03 | ABCG2, CA12, CA2, CA7, HIF1A, HTT, NPSR1, TP53 |
| BP | GO:0008152; metabolic process | GO:0006691; leukotriene metabolic process | 3.040E-05 | 6.967E-03 | ABCC1, ALOX15, ALOX5 |
| MF | GO:0005488; binding | GO:0051879; Hsp90 protein binding | 3.349E-05 | 7.519E-03 | AHR, HIF1A, NR3C1 |
| BP | GO:0009987; cellular process | GO:0034599; cellular response to oxidative stress | 3.722E-05 | 8.258E-03 | AKR1B1, CYP1B1, DAPK1, NOX4, TP53 |
| MF | GO:0003824; catalytic activity | GO:0101020; estrogen 16-alpha-hydroxylase activity | 3.755E-05 | 8.258E-03 | CYP1A1, CYP3A4 |
| CC | GO:0043226; organelle | GO:0043231; intracellular membrane-bounded organelle | 4.098E-05 | 8.835E-03 | ABCG2, AHR, AKR1B1, AR, CTDSP1, CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9, CYP3A4, ESRRA, FLT3, HIF1A, HTT, LMNA, NOX4, NPC1, NR0B1, NR3C1, PAX8, RAB9A, SMN1, SMN2, TDP1, TP53, TYR, XDH |
| BP | GO:0050896; response to stimulus | GO:0071495; cellular response to endogenous stimulus | 4.525E-05 | 9.660E-03 | AKR1B1, AR, FLT3, NOX4, NPC1, NR3C1, PAX8, TP53 |
| BP | GO:0009987; cellular process | GO:0010647; positive regulation of cell communication | 4.792E-05 | 9.945E-03 | AKR1B1, ALOX15, AR, CA2, CA7, CYP1B1, FLT3, HIF1A, HTT, NOX4, TP53, XDH |
| BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 4.795E-05 | 9.945E-03 | CA12, CA2, CA7 |
Enriched KEGG Pathways of Target Proteins (Activity≤10μM)
Top 10, ordered by adjusted p-value
Detailed Information of Enriched KEGG Pathways
| Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|
| hsa00140 | Steroid hormone biosynthesis_Homo sapiens_hsa00140 | 1.171E-09 | 8.763E-08 | HSD17B1; CYP1A2; HSD17B2; CYP1A1; CYP1B1; CYP3A4 |
| hsa00591 | Linoleic acid metabolism_Homo sapiens_hsa00591 | 2.164E-09 | 8.763E-08 | CYP2C9; CYP1A2; ALOX15; CYP3A4; CYP2C19 |
| hsa04913 | Ovarian steroidogenesis_Homo sapiens_hsa04913 | 3.750E-08 | 7.595E-07 | HSD17B1; ALOX5; HSD17B2; CYP1A1; CYP1B1 |
| hsa05204 | Chemical carcinogenesis_Homo sapiens_hsa05204 | 9.805E-09 | 2.647E-07 | CYP2C9; CYP1A2; CYP1A1; CYP1B1; CYP3A4; CYP2C19 |
| hsa00980 | Metabolism of xenobiotics by cytochrome P450_Homo sapiens_hsa00980 | 2.576E-07 | 4.173E-06 | CYP2C9; CYP1A2; CYP1A1; CYP1B1; CYP3A4 |
| hsa01100 | Metabolic pathways_Homo sapiens_hsa01100 | 1.817E-06 | 2.453E-05 | CYP2C9; HSD17B1; ALOX5; HSD17B2; CYP1A2; ALOX15; CYP1A1; AKR1B1; CYP2C19; CYP3A4; TYR; XDH |
| hsa00590 | Arachidonic acid metabolism_Homo sapiens_hsa00590 | 5.710E-06 | 5.781E-05 | CYP2C9; ALOX5; ALOX15; CYP2C19 |
| hsa00830 | Retinol metabolism_Homo sapiens_hsa00830 | 6.901E-06 | 6.211E-05 | CYP2C9; CYP1A2; CYP1A1; CYP3A4 |
| hsa00982 | Drug metabolism - cytochrome P450_Homo sapiens_hsa00982 | 8.764E-06 | 7.099E-05 | CYP2C9; CYP1A2; CYP3A4; CYP2C19 |
| hsa05200 | Pathways in cancer_Homo sapiens_hsa05200 | 9.499E-05 | 5.496E-04 | AR; PAX8; FLT3; DAPK1; HIF1A; TP53 |
| hsa04726 | Serotonergic synapse_Homo sapiens_hsa04726 | 5.939E-05 | 3.711E-04 | CYP2C9; ALOX5; ALOX15; CYP2C19 |
| hsa00380 | Tryptophan metabolism_Homo sapiens_hsa00380 | 5.956E-05 | 3.711E-04 | CYP1A2; CYP1A1; CYP1B1 |
| hsa05230 | Central carbon metabolism in cancer_Homo sapiens_hsa05230 | 2.787E-04 | 1.505E-03 | FLT3; TP53; HIF1A |
| hsa00910 | Nitrogen metabolism_Homo sapiens_hsa00910 | 4.225E-06 | 4.888E-05 | CA12; CA2; CA7 |
| hsa04976 | Bile secretion_Homo sapiens_hsa04976 | 3.308E-04 | 1.675E-03 | CA2; CYP3A4; ABCG2 |
| hsa05202 | Transcriptional misregulation in cancer_Homo sapiens_hsa05202 | 4.799E-03 | 1.851E-02 | PAX8; FLT3; TP53 |
| hsa05219 | Bladder cancer_Homo sapiens_hsa05219 | 2.751E-03 | 1.238E-02 | DAPK1; TP53 |
| hsa05215 | Prostate cancer_Homo sapiens_hsa05215 | 1.241E-02 | 4.568E-02 | AR; TP53 |
| hsa05216 | Thyroid cancer_Homo sapiens_hsa05216 | 1.382E-03 | 6.583E-03 | PAX8; TP53 |
| hsa00983 | Drug metabolism - other enzymes_Homo sapiens_hsa00983 | 3.451E-03 | 1.398E-02 | CYP3A4; XDH |
| hsa02010 | ABC transporters_Homo sapiens_hsa02010 | 3.162E-03 | 1.348E-02 | ABCC1; ABCG2 |
| hsa00232 | Caffeine metabolism_Homo sapiens_hsa00232 | 3.503E-05 | 2.579E-04 | CYP1A2; XDH |
Human Diseases Associated with the Target Proteins of the Plant (Activity≤10μM)
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Linked Targets |
|---|---|---|---|
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoarthritis | M15-M19, M47 | ALOX5 |
| C00-D49: Neoplasms | Oral cavity cancer | C00-C08 | TP53 |
| H00-H59: Diseases of the eye and adnexa | Choroidal neovascularisation | H35 | ESRRA |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Severe mood disorders | F30-F39 | NR3C1 |
| C00-D49: Neoplasms | Glioblastoma | NA | FLT3 |
| N00-N99: Diseases of the genitourinary system | Prostate hyperplasia | N40 | AR |
| L00-L99: Diseases of the skin and subcutaneous tissue | Pruritus | L29 | ALOX5 |
| C00-D49: Neoplasms | Prostate cancer | C61 | AR; AR; FLT3 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Psoriasis | L40 | ALOX5; FLT3 |
| J00-J99: Diseases of the respiratory system | Asthma | J45 | ALOX5; ALOX5; NR3C1; NR3C1; NR3C1; NR3C1; ESRRA |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthritis | M00-M25 | ALOX5; ABCC1; ESRRA |
| G00-G99: Diseases of the nervous system G00-G99 | Duchenne muscular dystrophy | G71.0 | NR3C1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | NR3C1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Cystic fibrosis | E84 | AR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic complication | E08-E13 | AKR1B1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic neuropathy | E11.40 | AKR1B1 |
| NA: NA | Non-infectious rhinitis | NA | NR3C1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CA2 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Depression | F30-F39 | NR3C1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | AKR1B1 |
| C00-D49: Neoplasms | Myeloid leukemia | C92 | FLT3 |
| C00-D49: Neoplasms | Lymphoma | C81-C86 | HIF1A |
| A00-B99: Certain infectious and parasitic diseases | Lymphatic filariasis | B74 | ALOX5 |
| C00-D49: Neoplasms | Leukemia | C90-C95 | FLT3 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Cushing's disease | E24.0 | NR3C1 |
| C00-D49: Neoplasms | Late-stage solid tumors | C00-C75, C7A, C7B, D10-D36, D3A | TP53 |
| K00-K95: Diseases of the digestive system | Gastrointestinal disease | K00-K93 | ESRRA |
| L00-L99: Diseases of the skin and subcutaneous tissue | Vitiligo | L80 | TYR |
| L00-L99: Diseases of the skin and subcutaneous tissue | Melasma | L81.1 | TYR |
| C00-D49: Neoplasms | Melanoma | C43 | TYR |
| NA: NA | GIST | NA | FLT3 |
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | AKR1B1 |
| C00-D49: Neoplasms | Gliosarcoma | NA | FLT3 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Male hormonal deficiencies | E20-E35 | AR |
| NA: NA | Male hypogonadism | NA | AR |
| A00-B99: Certain infectious and parasitic diseases | Bacterial infections | A00-B99 | CYP2C9 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Atopic dermatitis | L00-L99 | ALOX5; NR3C1 |
| C00-D49: Neoplasms | Female androgenresponsive recurrent mammary cancer | C50 | AR |
| NA: NA | Edema | NA | CA2 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Eczema | L20-L30 | NR3C1 |
| I00-I99: Diseases of the circulatory system | Edema associated with congestive heart failure | I50, R60.9 | CA2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Endocrine disease | E00-E35 | AR |
| G00-G99: Diseases of the nervous system G00-G99 | Encephalopathy | G93.4 | XDH |
| I00-I99: Diseases of the circulatory system | Renal artery disease | I70.1 | TP53 |
| C00-D49: Neoplasms | Metastatic prostate cancer | C61 | AR |
| I00-I99: Diseases of the circulatory system | Atherosclerosis | I70 | ALOX5 |
| H60-H95: Diseases of the ear and mastoid process | Hearing disorder | H90.5 | TP53 |
| C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | TP53; AKR1B1 |
| I00-I99: Diseases of the circulatory system | Heart failure | I50 | AR; XDH |
| G00-G99: Diseases of the nervous system G00-G99 | Ataxia telangiectasia | G11.3 | NR3C1 |
| K00-K95: Diseases of the digestive system | Duodenal ulcers | K25-K27 | CA2 |
| C00-D49: Neoplasms | Metastatic castration-resistant prostate cancer | C61 | AR |
| C00-D49: Neoplasms | Colon cancer | C50 | FLT3 |
| C00-D49: Neoplasms | Hematological malignancies | C81-C86 | TP53 |
| C00-D49: Neoplasms | Colorectal cancer | C18-C21 | TP53; FLT3 |
| NA: NA | Hematopoietic stem cell transplantation | NA | FLT3 |
| C00-D49: Neoplasms | Hormone refractory prostate cancer | C61 | AR |
| NA: NA | HIV infections | NA | AHR |
| I00-I99: Diseases of the circulatory system | High blood pressure | I10-I16 | CA2 |
| NA: NA | Corticosteroid-responsive inflammation | NA | NR3C1 |
| C00-D49: Neoplasms | Myelofibrosis | C94.4, D47.4 | FLT3 |
| A00-B99: Certain infectious and parasitic diseases | Fungal infections | B35-B49 | ALOX5; RAB9A |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic cataract | E10.36, E11.36 | AKR1B1 |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Cachexia | R64 | AR; ESRRA |
| I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | NPSR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hypogonadism | E23.0, E28.3, E29.1 | AR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperuricemia | E79.0 | XDH |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperuricaemia in gout | E79.0, M10 | XDH |
| E00-E89: Endocrine, nutritional and metabolic diseases | Testosterone deficiency | E29.1 | AR |
| I00-I99: Diseases of the circulatory system | Thrombosis | I80-I82 | ALOX5 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Inflammation | E08-E13, E10.2, E11, E11.2, E13.2, I73.9, I80-I82, N00-N29, G89 | ALOX5; NR3C1 |
| C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | ALOX5; NR3C1 |
| C00-D49: Neoplasms | Acute lymphoblastic leukemia | C91.0 | FLT3 |
| C00-D49: Neoplasms | Pancreatic cancer | C25 | FLT3 |
| C00-D49: Neoplasms | Cancer | C00-C96 | AR; HIF1A; TP53; FLT3; FLT3; NR3C1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Muscle atrophy | M62.5 | AR |
| G00-G99: Diseases of the nervous system G00-G99 | Multiple scierosis | G35 | NR3C1 |
| C00-D49: Neoplasms | Multiple myeloma | C90 | AHR |
| H00-H59: Diseases of the eye and adnexa | Ocular disease | H00-H59 | NR3C1 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Spinal cord injury | S14, S24, S34 | NR3C1 |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | HIF1A; TP53; FLT3 |
| G00-G99: Diseases of the nervous system G00-G99 | Spinal muscular atrophy | G00-G99 | SMN1;SMN2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hormone deficiency | E00-E90 | AR |
| Z00-Z99: Factors influencing health status and contact with health services | Contraception | Z30 | AR |
| I00-I99: Diseases of the circulatory system | Cardiovascular disorder | I00-I99 | AR |
| C00-D49: Neoplasms | Castration-resistant prostate cancer | C61 | AR |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Skin allergies | T78.4 | NR3C1 |
| C00-D49: Neoplasms | Advanced prostate cancer | C61 | AR |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Toxicity | T36-T50, T51-T65 | TP53 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Schizophrenia | F20 | ESRRA |
| C00-D49: Neoplasms | Bladder cancer | C67 | AR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Non-insulin dependent diabetes | E11.9 | ESRRA |
| L00-L99: Diseases of the skin and subcutaneous tissue | Dermatitis | L20-L30 | ALOX5; NR3C1; ESRRA |
| L00-L99: Diseases of the skin and subcutaneous tissue | Dermatological disease | L00-L99 | AR; NR3C1; ESRRA |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Gout | M10 | XDH; AKR1B1; ABCC1; ABCC1 |
| C00-D49: Neoplasms | Breast cancer | C50 | AR; FLT3; FLT3 |
| J00-J99: Diseases of the respiratory system | Rhinitis | J00, J30, J31.0 | ALOX5; NR3C1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | ALOX5; TYR; AKR1B1; NR3C1; ESRRA |
| C00-D49: Neoplasms | AML | NA | FLT3 |
| J00-J99: Diseases of the respiratory system | Allergic rhinitis | J00, J30, J31.0, T78.4 | NR3C1; ESRRA |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Allergy | T78.4 | ALOX5 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Alopecia | L65.9 | AR |
| H60-H95: Diseases of the ear and mastoid process | Otitis externa | H60 | NR3C1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoporosis in post-menopausal women | M80-M81 | AR |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoporosis | M80-M81, Z79.890 | AR |
| J00-J99: Diseases of the respiratory system | Chronic obstructive pulmonary disease | J40-J44, J47 | ALOX5; NR3C1; NR3C1; NR3C1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Xerophthalmia | E50.6-E50.7 | NR3C1 |
| J00-J99: Diseases of the respiratory system | Respiratory disease | J00-J99 | ALOX5 |
| J00-J99: Diseases of the respiratory system | Airway inflammation | J00-J99 | FLT3 |
| K00-K95: Diseases of the digestive system | Alcoholic hepatitis | K70.1 | AR |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | AR |
| C00-D49: Neoplasms | CLL | NA | FLT3 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | CYP3A4; NR3C1 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Acne vulgaris | L70.0 | AR; AR; ESRRA |
| H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | CA2 |
| I00-I99: Diseases of the circulatory system | Pulmonary arterial hypertension | I27.0, I27.2 | HIF1A |
| A00-B99: Certain infectious and parasitic diseases | Human immunodeficiency virus infection | B20-B26 | FLT3 |
| C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | TP53; TP53; FLT3; FLT3 |
| NA: NA | Anaplastic mixed oligoastrocytoma | NA | FLT3 |